118684-31-4

Basic information

• Product Name: BOC-3-AMINOBENZYLALCOHOL
• Synonyms: BOC-3-AMINOBENZYLALCOHOL;TERT-BUTYL 3-(HYDROXYMETHYL)PHENYLCARBAMATE;3-(Boc-aMino)benzyl alcohol;ert-Butyl (3-(hydroxymethyl)phe nyl)carbamate
• CAS NO: 118684-31-4
• Molecular Formula: C₁₂H₁₇NO₃
• Molecular Weight: 223.27
• Mol File: 118684-31-4.mol

Chemical Properties

• Melting Point: 98 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6))
• Boiling Point: 309.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.161±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.71±0.70(Predicted)
• CAS DataBase Reference: BOC-3-AMINOBENZYLALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-3-AMINOBENZYLALCOHOL(118684-31-4)
• EPA Substance Registry System: BOC-3-AMINOBENZYLALCOHOL(118684-31-4)

Safety Data

• Hazardous Substances Data: 118684-31-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-3-aminobenzyl alcohol is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures that can target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, BOC-3-aminobenzyl alcohol serves as a crucial component in the development of new pesticides and other agricultural chemicals, enhancing crop protection and yield.
Used in Fine Chemicals Production:
BOC-3-aminobenzyl alcohol is utilized as a building block in the production of fine chemicals, which are high-purity chemicals used in various applications, including fragrances, flavors, and dyes.
Used in Peptidomimetics Synthesis:
BOC-3-aminobenzyl alcohol is employed as a structural element in the synthesis of peptidomimetics, which are compounds that mimic the properties of peptides but offer improved stability and bioavailability.
Used in Organometallic Catalysts Development:
BOC-3-AMINOBENZYLALCOHOL is also used in the development of organometallic catalysts, which are essential in various chemical reactions, particularly in the fields of polymerization and cross-coupling reactions, to improve reaction efficiency and selectivity.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1877-77-6 3-aminobenzenemethanol 
• 111331-82-9 3-[(tert-butoxycarbonyl)amino]benzoic acid 
• 50-00-0 formaldehyd 
• 159624-15-4 tert-butyl N-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 
• 4518-10-9 Methyl 3-aminobenzoate 
• 691-64-5 di-tert-butyl oxalate 
• 161111-23-5 tert-butyl 3-(methoxycarbonyl)phenylcarbamate 
• 344462-84-6 tert-butyl [3-(ethoxycarbonyl)phenyl]carbamate 

Downstream Products

• 118684-32-5 [3-[N-(tert-butoxycarbonyl)amino]phenyl]methyl bromide 
• 188751-44-2 3-N-((tert-butyloxy)carbonylamino)benzyl-4-nitrophenyl carbonate 
• 847225-59-6 2-nitro-3-(3-t-butoxycarbonylaminobenzyloxy)pyridine 
• 1011531-62-6 tert-butyl 3-((4-((S)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-1-(isoxazol-3-yl)-3-oxopropyl)phenoxy)methyl)phenylcarbamate 
• 847225-57-4 2-nitro-3-(3-aminobenzyloxy)pyridine 
• 299217-20-2 3-(3'-N-BOC-aminobenzyloxy)-5-hydroxybenzyl alcohol 
• 299217-22-4 3-(3'-N-BOC-aminobenzyloxy)-5-i-pentyloxybenzyl bromide 
• 299217-21-3 3-(3'-N-BOC-aminobenzyloxy)-5-i-pentyloxybenzyl alcohol 
• 299217-37-1 8-[3'-(3-i-pentyloxy)-5'-(3''-aminobenzyloxy)benzyloxy]-2-[1H]-quinolinone 
• 299217-23-5 8-[3'-(i-pentyloxy)-5'-(3''-N-BOC-aminobenzyloxy)benzyloxy]-2-[1H]-quinolinone 
• 299217-25-7 8-[3'-(i-pentyloxy)-5'-(3''-aminobenzyloxy)benzyloxy]-2-[1-(3'''-acetoxybenzyl)]-quinolinone 
• 299217-32-6 8-[3'-(3-i-pentyloxy)-5'-(3''-aminobenzyloxy)benzyloxy]-2-[1-(4'''-acetoxyphenyl)ethyl]quinolinone 
• 299217-38-2 C₃₉H₄₈N₄O₈ 
• 299217-24-6 8-[3'-(i-pentyloxy)-5'-(3''-N-BOC-aminobenzyloxy)benzyloxy]-2-[1-(3'''-acetoxybenzyl)]-quinolinone 

Relevant articles and documents

Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors

A strong relationship between abnormal functions of Aurora kinases and tumorigenesis has been reported for decades. Consequently, Aurora kinases serve as potential targets for anticancer agents. Here, we identified aminobenzothiazole derivatives as novel inhibitors of Aurora B kinase through bioisosteric replacement of the previous inhibitors, aminobenzoxazole derivatives. Most of the urea-linked aminobenzothiazole derivatives showed potent and selective inhibitory activity against Aurora B kinase over Aurora A kinase. Molecular modeling indicated that compound 15g bound well to the active site of Aurora B kinase and formed the essential hydrogen bonds. The potent compounds, 15g and 15k, were selected, and their biological effects were evaluated using HeLa cell lines. It was found that these compounds inhibited the phosphorylation of histone H3 at Ser10 and induced G2/M cell cycle arrest. We suggest that the reported compounds have the potential to be further developed as anticancer therapeutics.

PEGylated Poly-HDACi: A Designer Polyprodrug from Optimized Drug Units**

We designed, synthesized, and characterized a tri-block copolymer. Its hydrophobic part, a chain of histone deacetylase inhibitor (HDACi) prodrug, was symmetrically flanked by two identical PEG blocks, whereas the built-in HDACi was a linear molecule, terminated with a thiol at one end, and a hydroxyl group at the other. Such a feature facilitated end-to-end linkage of prodrugs through alternatively aligned disulfides and carbonates. The disulfides served dual roles: redox sensors of smart nanomedicine, and warheads of masked HDACi drugs. This approach, carefully designed to benefit both control-release and efficacy, is conceptually novel for optimizing drug units in nanomedicine. Micelles from this designer polyprodrug released only PEG, CO2 and HDACi, and synergized with DOX against HCT116 cells, demonstrating its widespread potential in combination therapy. Our work highlights, for the first time, the unique advantage of thiol-based drug molecules in nanomedicine design.

Adenosine receptor antagonists

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compounds of formula (I) of the present invention are useful as adenosine receptor inhibitors, especially A2A and/or A2B inhibitors, for example, the product can be used for prevention or treatment of diseases associated with A2A and/or A2B activity or expression.

HETEROARYL COMPOUNDS AS KINASE INHIBITOR

Provided herein are heteroaryl compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R 1, R 2, R 3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

SUBSTITUTED TETRAHYDROPYRIDINE DERIVATIVES AS IDO-1 INHIBITORS AND USES THEREOF

Compounds of formula I that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase, pharmaceutical compositions including such compounds and methods of treating diseases, conditions or disorders utilizing such compounds and compositions.

Preparation of acetals from aldehydes and alcohols under basic conditions

A new, simple protocol for the synthesis of acetals under basic conditions from non-enolizable aldehydes and alcohols has been reported. Such reactivity is facilitated by a sodium alkoxide along with a corresponding trifluoroacetate ester, utilizing formation of sodium trifluoroacetate as a driving force for acetal formation. The usefulness of this protocol is demonstrated by its orthogonality with various acid-sensitive protecting groups and by good compatibility with functional groups, delivering synthetically useful acetals complementarily to the synthesis under acidic conditions from aldehydes and alcohols.

N-PHENYLALKOXY-7-OXO-6-SULFOOXY-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

Compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, their preparation, pharmaceutical compositions comprising such compounds and their use in treating and/or preventing bacterial infections are disclosed.

Palladium-Catalyzed Suzuki–Miyaura Cross-Coupling of Secondary α-(Trifluoromethyl)benzyl Tosylates

A palladium-catalyzed C(sp3)?C(sp2) Suzuki–Miyaura cross-coupling of aryl boronic acids and α-(trifluoromethyl)benzyl tosylates is reported. A readily available, air-stable palladium catalyst was employed to access a wide range of functionalized 1,1-diaryl-2,2,2-trifluoroethanes. Enantioenriched α-(trifluoromethyl)benzyl tosylates were found to undergo cross-coupling to give the corresponding enantioenriched cross-coupled products with an overall inversion in configuration. The crucial role of the CF3 group in promoting this transformation is demonstrated by comparison with non-fluorinated derivatives.

GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.